Extranodal NK-T-cell lymphoma future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Overview
High dose chemotherapy and autologous haematopoietic stem cell transplantation is used for varying types of lymphoma, however there is a lac of such experience in treating extranodal NK-T cell lymphoma. Further clinical trials are needed to prove that this therapy is handy and can be used as a method of therapy. Autologous transplantation appears to provide a great survival benefit only for those who attended a complete remission at the time of transplantation.
Future or Investigational Therapies
Future or Investigational Therapies
High dose chemotherapy and autologous haematopoietic stem cell transplantation is used for varying types of lymphoma, however there is a lac of such experience in treating extranodal NK-T cell lymphoma.[1] Further clinical trials are needed to prove that this therapy is handy and can be used as a method of therapy. Autologous transplantation appears to provide a great survival benefit only for those who attended a complete remission at the time of transplantation.
References
References
- ↑ Liang, Raymond (2009). “Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type”. British Journal of Haematology. 147 (1): 13–21. doi:10.1111/j.1365-2141.2009.07802.x. ISSN 0007-1048.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH